1 of 3 daily views used · 2 remaining. Refreshes and chart changes do not use another view.
Daily close · 2026-11-16
Price return
Both stocks start at 0% on the first shared trading day.
BAX-70.93%
TMCI-82.69%
Use left and right arrow keys to inspect historical line observations. Financial bars can be focused individually.
Split-adjusted closing prices. Dividends are excluded.Year ranges begin January 1 of the end year minus the selected years.
AURORA
Ask about these stocks.
↗
CONTEXT ATTACHEDBAX + TMCIPrices, financials and SEC filing evidence
Similarity
56.3%
3 shared / 6 total tags
How similar are their businesses?
The score compares business activities in annual filings released in 2025. Core activities receive four times the weight of material activities. Industries that fewer companies share carry more weight.
Positive activities from the two selected annual filings. Expand each group to view all its activities, or use the complete table below. These are classification sets, not revenue shares. The weighted similarity score also accounts for exposure and how common each activity is.Show business activity table · 6 rows, 3 columns
Core activities receive full weight; material activities receive one quarter. Select a tag to read the filing evidence.
Business activity
BAX
TMCI
Core
Core
Core
Core
Core
Material
Material
Not tagged
Core
Not tagged
Material
Not tagged
What each company does
Compare the businesses
BI
Baxter International Inc.
BAX · XNYS
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Price return uses split-adjusted daily closes and excludes dividends. Both stocks start on the first shared trading day within the selected window. Unavailable metrics leave gaps.
Financials use SEC canonical statements available by the displayed cutoff, retaining each company's fiscal period end. Annual and quarterly amounts are shown separately. P/E is unavailable when earnings do not support a positive ratio.
Business overlap uses industry tags from annual filings released in 2025. Each core activity receives full weight; each material activity receives one quarter of that weight. Rarer industries carry more weight. We sum the smaller exposure for each shared activity and divide it by the sum of the larger exposure for every activity in either company. This measures business overlap, rather than price correlation or expected returns.
Search eligibility requires distinct issuers, a shared core category and at least 20% weighted overlap, supported by industry or sector evidence and specific business activities. Broad classifications require stronger overlap within the same sector. Comparisons also need at least 252 shared price observations within two years, recent trading and a common sourced revenue or net-income trend. Missing P/E or gross margin alone does not exclude a comparison. The eligibility snapshot refreshes daily. Related comparisons use a separate, stricter peer rule; their ten-peer discovery limit does not limit search eligibility. Other stock pairs remain available in the comparison tool.
Statements available through 2026-11-17. Industry snapshot: 2025-12-31 · 5,721 classified issuers.